Haisco licenses obesity drug HSK47388 to new US biotech in deal worth up to $1.12 billion
- nuaxia
- 12 hours ago
- 3 min read
The agreement gives a newly formed company backed by Population Health Partners and ARCH Venture Partners ex-China rights to Haisco’s Phase II-ready oral THR-β agonist for obesity and metabolic disorders.
Haisco Pharmaceutical has granted a newly established US biotechnology company founded by Population Health Partners and ARCH Venture Partners exclusive ex-China rights to develop and commercialise HSK47388, an oral thyroid hormone receptor beta (THR-β) agonist being developed for obesity and related metabolic diseases.
Haisco will receive $120 million upfront and near-term payments and is eligible for development and commercial milestones that could take total payments above $1.12 billion, plus royalties on future net sales.
Field | Content |
Alert Type | Deal |
Companies | Haisco Pharmaceutical; newly formed US biotechnology company founded by Population Health Partners and ARCH Venture Partners |
Deal Type | Exclusive licensing agreement |
Asset or Company | HSK47388 |
Therapy Area(s) | Obesity; Metabolic disease |
Technology or Modality | Oral small-molecule thyroid hormone receptor beta (THR-β) agonist |
Deal Value | Haisco will receive $120 million in upfront and near-term payments and is eligible for additional development and commercial milestone payments that could bring total payments to more than $1.12 billion, plus tiered royalties on future net sales. The milestone component is contingent and should not be treated as guaranteed consideration. |
Development Stage | Phase II-ready |
Geography | Worldwide excluding Greater China |
What Happened | On 26 August 2026, Haisco announced an exclusive licensing agreement covering HSK47388 with a newly formed US biotechnology company founded by Population Health Partners and ARCH Venture Partners. The new company receives exclusive rights to develop and commercialise HSK47388 outside Greater China, while Haisco retains rights in Greater China. Haisco will receive $120 million in upfront and near-term payments, with development and commercial milestones potentially taking total payments above $1.12 billion, in addition to royalties on net sales. |
Why It Matters | The agreement moves a China-originated metabolic programme into a separately financed US company backed by experienced life-sciences investors and provides a route for global development outside Greater China. HSK47388 targets THR-β rather than the incretin pathways used by established GLP-1-based obesity medicines, potentially providing a complementary approach to weight management if its early clinical profile is confirmed in larger studies. |
Supporting Context | HSK47388 is a selective oral THR-β agonist designed to increase energy expenditure and improve lipid metabolism while limiting unwanted THR-α-associated effects. Haisco has reported early clinical findings supporting further development in obesity, but the candidate remains investigational and its efficacy and safety require confirmation in later-stage trials. |
Strategic Rationale | The new US company gains exclusive ex-Greater China rights to a Phase II-ready metabolic asset without having to build the programme from discovery, while Haisco receives substantial near-term consideration and retains Greater China rights alongside milestone and royalty participation in international markets. The involvement of Population Health Partners and ARCH Venture Partners provides dedicated capital and development expertise for the programme’s global advancement. |
Potential Impact | If later-stage trials confirm meaningful weight loss and metabolic benefits, HSK47388 could provide a differentiated oral approach within the rapidly expanding obesity market and potentially be evaluated alongside incretin-based therapies. Its eventual clinical and commercial role remains dependent on successful development and regulatory approval. |
Key Takeaway | Haisco’s licensing agreement puts more than $1.12 billion of potential economics behind an ex-China obesity programme built around an oral, non-incretin mechanism. |
What to Watch | Formation and naming of the new US company, initiation of Phase II development for HSK47388 and clinical evidence showing whether THR-β activation can deliver meaningful weight loss with an acceptable safety profile. |
Primary Source | |
Relevant Date | 26 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments